Company Overview of Akrimax Pharmaceuticals, LLC
Akrimax Pharmaceuticals, LLC, a pharmaceutical company, develops, produces, and distributes pharmaceutical products. It offers InnoPran XL, extended release capsules that controls blood pressure and heart rate; Suprenza, an orally disintegrating tablet; Primlev, an oxycodone HCI/acetaminophen for the treatment of liver failure; Tirosint, levothyroxine sodium capsules for the treatment of hypothyroidism and Pituitary thyrotropin-stimulating hormone suppression; NitroMist, a nitroglycerin lingual spray for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease; and Inderal LA, a long-acting form of propranolol used for that treatment of angina pectoris...
11 Commerce Drive
Cranford, NJ 07016
Founded in 2007
Key Executives for Akrimax Pharmaceuticals, LLC
Co-Founder and Vice Chairman
Vice President of Operations
Chief Scientific Officer, Corporate Vice President and Consultant
Compensation as of Fiscal Year 2014.
Akrimax Pharmaceuticals, LLC Key Developments
Akrimax Pharmaceuticals, LLC Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Akrimax Pharmaceuticals, LLC Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Akrimax Pharmaceuticals, LLC Announces New Data Highlight Use of Tirosint(R)
Jun 20 13
Akrimax Pharmaceuticals, LLC announced data that show a lower dose of Tirosint(R) (levothyroxine sodium) capsules is required as compared with standard T4 tablets for hypothyroidism patients with impaired gastric acid secretion to reach their target thyroid-stimulating hormone (TSH) levels. The American Association of Clinical Endocrinologist (AACE) Guidelines for Clinical Practice for Evaluation and Treatment of Hypothyroidism call for physicians to treat hypothyroidism with oral levothyroxine replacement therapy. Careful dose titration and monitoring is necessary in order to maintain a euthyroid state, while avoiding adverse events due to overtreatment.(1) TSH levels in patients receiving levothyroxine should be no more than 4.0 mU/L.(2). The pilot study examined patients who had T4 malabsorption and were in T4 treatment for more than 5 years with the same brand of tablets. A total of 36 patients met the study criteria, and 30 (28 females /2 males; median age=51 years; median T4 dose=2.05 mg/kg/day) completed the study. T4 treatment was switched from the usual tablets to a lower dose of the softgel T4 capsules (median T4 dose=1.77 mg/kg/day; p=0.0082). Thyroid function and TSH were measured before and after 3, 6, 12 and 18 months from the treatment switch. A slight serum TSH increase was observed in some patients after 3 months of treatment, with no change in Free T4 (FT4) levels. After 6 months, however, despite the reduced dose of T4, mean TSH values were similar (1.82 vs. 1.86 mU/l) in about two out of three patients (responders n=21) and so remained until the end of the study. In all of the remaining patients (non-responders n=9), TSH levels were significantly higher than baseline values throughout the study. In 4 of them, additional intestinal disorders were detected. Mean levels of FT4 and FT3 were in the normal range and not significantly modified throughout the study.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries